Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senexis Ltd.

This article was originally published in Start Up

Executive Summary

Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.

You may also be interested in...



AC Immune SA

Swiss-based AC Immune SA is using both an immunological and a small molecule approach to tackling Alzheimer's disease. It hopes that both techniques may lead to compounds that may, by re-balancing the equilibrium between mutant and harmless forms of the protein amyloid beta, halt and perhaps even reverse the progression of the disease.

AC Immune SA

Swiss-based AC Immune SA is using both an immunological and a small molecule approach to tackling Alzheimer's disease. It hopes that both techniques may lead to compounds that may, by re-balancing the equilibrium between mutant and harmless forms of the protein amyloid beta, halt and perhaps even reverse the progression of the disease.

Addressing Alzheimer's

Fresh insights and tools are empowering start-ups pursuing treatments for Alzheimer's disease.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel